首页|Is Riparin III a promising drug in the treatment for depression

Is Riparin III a promising drug in the treatment for depression

扫码查看
原文链接
  • NSTL
  • Elsevier
Stress is crucially related to the pathophysiology of mood disorders, including depression. Since the effectiveness and number of the current pharmacological options still presents significant limitations, research on new substances is paramount. In rodents, several findings have indicated that corticosterone administration induces the manifestation of behavioral and neurochemical aspects of depression. Recently, riparin III has shown antidepressant-like properties in trials performed on animal models. Thus, our goal was to investigate the effects of riparin III on behavioral tests, monoamines levels, oxidative stress and cytokines levels in chronic corticosterone-induced model of depression. To do this, female swiss mice were treated with subcutaneous administration of corticosterone for 22 days. In addition, for the last 10 days, riparin III or fluvoxamine were also administered per os in specific test groups. Control groups received subcutaneous saline injections or distilled water per os. At the end of the timeline, the animals were killed and their hippocampi, prefrontal cortex, and striatum dissected for neurochemical analysis. Brain changes following corticosterone administration were confirmed, and riparin III could reversed the most abnormal behavioral and neurochemical corticosteroneinduced alterations. These results suggest the potential antioxidant, anti-inflammatory and antidepressant effects of riparin III after a chronic stress exposure.

DepressionCorticosteroneRiparin IIICytokinesOxidative stressMonoamines

Vasconcelos Mallmann, Auriana Serra、Chaves, Raquell de Castro、de Oliveira, Natalia Ferreira、Maia Oliveira, Iris Cristina、Cavalcanti Capibaribe, Victor Celso、Valentim, Jose Tiago、Alves da Silva, Daniel Moreira、Sartori, Danusio Pinheiro、Rodrigues, Gabriel Carvalho、Maia Chaves Filho, Adriano Jose、Riello, Giovana Barbosa、de Franca Fonteles, Marta Maria、Mendes Vasconcelos, Silvania Maria、Macedo, Danielle、Chavez Gutierrez, Stanley Juan、Barbosa Filho, Jose Maria、Rodrigues de Carvalho, Alyne Mara、Florenco de Sousa, Francisca Clea

展开 >

Univ Fed Ceara, Fac Med, Drug Res & Dev Ctr, Neuropsychopharmacol Lab, Fortaleza, Ceara, Brazil

Univ Fed Ceara, Fac Med, Dept Physiol & Pharmacol, Fortaleza, Ceara, Brazil

Univ Fed Ceara, Drug Res & Dev Ctr, Multiuser Facil, Fortaleza, Ceara, Brazil

Univ Fed Piaui, Pharmaceut Sci Dept, Teresina, Piaui, Brazil

Univ Fed Paraiba, Lab Pharmaceut Technol, Joao Pessoa, Paraiba, Brazil

展开 >

2021

10.1016/j.ejps.2021.105824

European journal of pharmaceutical sciences

European journal of pharmaceutical sciences

ISTP
ISSN：0928-0987
年,卷(期)：2021.162
  • 1
  • 55